II
CRXT

Ibex Investors’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Ibex Investors’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-34,900
Closed -$351K – 104
2021
Q1 		$351K Buy
+34,900
New +$352K 0.12% 68

Other funds holding CRXT

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Ibex Investors's CRXT Position: Q2 2021 in Review

Ibex Investors sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q2 2021, closing a stake of 34,900 shares — an estimated $351K sold.

Ibex Investors first reported a position in CRXT in Q1 2021 and held it in 1 quarter. The position peaked at $351K in Q1 2021. 33 funds tracked by Wall St. Rank hold CRXT as of Q2 2021.

  • Ibex Investors reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Ibex Investors sold 34,900 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q2 2021, an estimated $351K.
  • Ibex Investors first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Ibex Investors's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $351K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q2 2021.

Based on Ibex Investors's 13F filing for Q2 2021, filed 5 Aug 2021.